Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NICE Decision On Arthritis Opens Door For Biosimilars

UK Recommends Treating Moderate Rheumatoid Arthritis With Three Biologic Molecules

Executive Summary

A decision by the UK’s NICE opens the door to broaden the use of adalimumab, etanercept and infliximab by using them to treat moderate as well as severe rheumatoid arthritis.

You may also be interested in...



Fixing The UK Market: Government Must Move From ‘Transactional’ To ‘Strategic’ Approach

With the UK market experiencing approval delays, shortages, and regulatory complexity, the government’s “policy vacuum” and complacent approach to off-patent medicines risk undermining the sector, says BGMA chair Diane DiGangi Trench. In an exclusive interview with Generics Bulletin, she urges a shift from a “transactional” to a “strategic” relationship with industry to fully unlock the benefits of generics and biosimilars.

European Biosimilars Have ‘Room To Grow’ On Access And Understanding

In terms of broadening both access to treatment and stakeholder understanding, there remains plenty of room for growth for biosimilars in Europe, Medicines for Europe director general Adrian van den Hoven tells Generics Bulletin in an exclusive interview.

How Samsung Bioepis Is Laying A Path For Ophthalmic Biosimilars

With the first approved rival to Lucentis in both the EU and US, Samsung Bioepis is laying the groundwork for biosimilars to break into ophthalmology ahead of launching its Byooviz version of ranibizumab, explains vice-president of commercial strategy Josh Lee.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151004

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel